This article is from the source 'guardian' and was first published or seen on . The next check for changes will be

You can find the current article at its original source at https://www.theguardian.com/business/2025/may/07/wegovy-maker-novo-nordisk-cuts-profit-forecast

The article has changed 4 times. There is an RSS feed of changes available.

Version 1 Version 2
Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
(about 3 hours later)
Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli LillySlowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly
Denmark’s Novo Nordisk has cut its annual revenue and profit forecasts after disappointingly “flabby” sales of its weight loss drug Wegovy, as US prescriptions tailed off amid fierce competition. Denmark’s Novo Nordisk has cut its annual revenue and profit forecasts after disappointingly “flabby” sales of its weight loss drug Wegovy, as US prescriptions tailed off.
A boom in sales of Wegovy and the diabetes medication Ozempic helped to turn the pharmaceutical company into Europe’s most valuable listed company, worth $615bn (£461bn) at its peak. A boom in sales of Wegovy and the diabetes medication Ozempic helped to turn the drugmaker into Europe’s most valuable listed company, worth $615bn (£461bn) at its peak last year.
However, prescriptions in the US, its biggest market, have not grown since February, even though Novo Nordisk increased production of Wegovy to meet demand for the slimming drug. Its market value has halved to about $310bn.However, prescriptions in the US, its biggest market, have not grown since February, even though Novo Nordisk increased production of Wegovy to meet demand for the slimming drug. Its market value has halved to about $310bn.
A slowdown in forecast sales growth is likely to deepen investor concerns that Denmark’s biggest company is losing market share to its US rival Eli Lilly, which makes the diabetes and obesity drugs Mounjaro and Zepbound.A slowdown in forecast sales growth is likely to deepen investor concerns that Denmark’s biggest company is losing market share to its US rival Eli Lilly, which makes the diabetes and obesity drugs Mounjaro and Zepbound.
Susannah Streeter, a Hargreaves Lansdown analyst, said the anti-obesity drugmaker Novo Nordisk “looked like a lean profit machine but its sales are turning flabbier as main rival Eli Lily gains more muscle in the space”. Susannah Streeter, a Hargreaves Lansdown analyst, said Novo Nordisk “looked like a lean profit machine but its sales are turning flabbier as main rival Eli Lily gains more muscle in the space”.
Wegovy was the first of a new wave of anti-obesity drugs – known as GLP-1s after the gut hormone they mimic – to hit the market. Sales of the injectable drug totalled 17.36bn Danish kroner (£1.98bn) between January and March, down by 13% from the previous quarter. This was below the 18.7bn kroner forecast by analysts.Wegovy was the first of a new wave of anti-obesity drugs – known as GLP-1s after the gut hormone they mimic – to hit the market. Sales of the injectable drug totalled 17.36bn Danish kroner (£1.98bn) between January and March, down by 13% from the previous quarter. This was below the 18.7bn kroner forecast by analysts.
Overall revenues rose by 18%, and pre-tax profits advanced by 16% to 37bn kroner at constant exchange rates in the first quarter, but Novo said it was hit by compounding – medications made by pharmacies using the active ingredients of patented drugs.Overall revenues rose by 18%, and pre-tax profits advanced by 16% to 37bn kroner at constant exchange rates in the first quarter, but Novo said it was hit by compounding – medications made by pharmacies using the active ingredients of patented drugs.
The Danish company now expects 13% to 21% sales growth this year, down from the 16% to 24% range given at the start of the year. Operating profits are expected to rise by 16% to 24%, compared with the previous estimate of 19% to 27%. This began in the US after the drugs regulator declared shortages of Wegovy, Ozempic and Zepbound, allowing patients to buy compounded products for as little as $199 a month, while the branded drugs cost more than $1,000. The shortage has since eased.
Analysts are forecasting that sales and operating profit this year will grow by 17.8% and 21.5%, respectively. Derren Nathan, the head of equity research at Hargreaves Lansdown, said: “There’s a clampdown on compounders, but question marks remain over its enforcement. The end of the shortage also raises questions about the health of US demand. That’s also reflected in Novo’s deal last week with a US healthcare provider to provide Wegovy to patients at a discounted rate of $499.”
The Danish company now expects 13% to 21% sales growth this year, down from the 16% to 24% range given at the start of the year. Operating profits are expected to rise by 16% to 24%, compared with the previous estimate of a 19% rise to 27%.
Analysts are forecasting that sales and operating profit this year will grow by 17.8% and 21.5% respectively.
Novo’s chief executive, Lars Fruergaard Jørgensen, said: “In the first quarter of 2025 we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US.”Novo’s chief executive, Lars Fruergaard Jørgensen, said: “In the first quarter of 2025 we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US.”
The company’s finance chief said he was sceptical that Donald Trump’s executive order to reduce the time it takes to approve pharmaceutical factories in the country would significantly change timelines for the industry. The company’s finance chief said he was sceptical that Donald Trump’s executive order to reduce the time it takes to approve pharmaceutical factories in the US would significantly change timelines for the industry.
Trump signed the executive order on Monday, as part of new regulations to encourage international drugmakers to shift their operations to the country.
Karsten Munk Knudsen said it takes years for a pharmaceutical company to build a factory in compliance with the quality protocols set and enforced by the US Food and Drug Administration. “We would welcome if there are more pragmatic ways through it, but I’m sceptical that it will markedly change timelines in our industry,” he added.
Sign up to Business TodaySign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morningGet set for the working day – we'll point you to all the business news and analysis you need every morning
after newsletter promotionafter newsletter promotion
The trade group PhRMA estimates it takes five to 10 years to build a new pharmaceutical plant in the US. Trump signed the executive order on Monday, as part of new regulations to encourage international drugmakers to shift their operations to the country.
Derren Nathan, the head of equity research at Hargreaves Lansdown, said: “Novo Nordisk has lashed out at the controversial US compounding industry in its quarterly update, citing a focus on preventing unlawful formulations of semaglutide, the active ingredient in its weight-loss wonder jab Wegovy. Karsten Munk Knudsen said it takes years for a pharmaceutical company to build a factory in compliance with the quality protocols set and enforced by the US Food and Drug Administration. “We would welcome if there are more pragmatic ways through it, but I’m sceptical that it will markedly change timelines in our industry,” he said.
“In some cases, US compounding pharmacies are allowed to formulate active medical ingredients into non-approved drugs to meet individual requirements or combat shortfalls in supply.” The Danish firm also abandoned its global gender goals in the US, after Trump’s executive orders to stop diversity, equity and inclusion (DEI) initiatives. Other European drugmakers – GSK, Roche and Novartis – have taken similar steps.
Nathan said that while Wegovy’s sales growth in the US, at 39%, was “hardly pedestrian”, most of its growth was driven by sales in other markets. He said Novo faced “intense competition” from Eli Lilly to bring an oral alternative to Wegovy to market.Nathan said that while Wegovy’s sales growth in the US, at 39%, was “hardly pedestrian”, most of its growth was driven by sales in other markets. He said Novo faced “intense competition” from Eli Lilly to bring an oral alternative to Wegovy to market.
Competition is likely to heat up further with other drugmakers developing next-generation GLP-1 medications, and cheaper generic versions coming on to the market.Competition is likely to heat up further with other drugmakers developing next-generation GLP-1 medications, and cheaper generic versions coming on to the market.
Sheena Berry, a healthcare analyst at Quilter Cheviot, said: “Currently, the obesity market is still dominated by Eli Lilly and Novo Nordisk, but there are numerous clinical trials ongoing with competitors looking to enter the space.”Sheena Berry, a healthcare analyst at Quilter Cheviot, said: “Currently, the obesity market is still dominated by Eli Lilly and Novo Nordisk, but there are numerous clinical trials ongoing with competitors looking to enter the space.”